Paid Clinical Trials Madison
Discover 556 paid clinical trials in Madison, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06312176
Conditions
Breast Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab tirumotecan
Pembrolizumab
Paclitaxel
Nab-paclitaxel
Capecitabine
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Sponsor:
University of Wisconsin, Madison
Location:
Code:
NCT04573231
Conditions
Breast Cancer
HER2-negative Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
18F-DCFPyL
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
Sponsor:
Clarity Pharmaceuticals Ltd
Location:
Code:
NCT04023331
Conditions
Neuroblastoma
Relapsed Neuroblastoma
Refractory Neuroblastoma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
67Cu-SARTATE
64Cu-SARTATE
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Sponsor:
Ruth O'Regan
Location:
Code:
NCT04886531
Conditions
Breast Cancer
HER2-positive Breast Cancer
ER Positive Breast Cancer
PR-Positive Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Neratinib
Letrozole (L) or Anastrozole (A)
Trastuzumab
Pulmonary Hypertension Association Registry
Sponsor:
Pulmonary Hypertension Association, Inc.
Location:
Code:
NCT04071327
Conditions
Pulmonary Arterial Hypertension
Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Hypertension
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Comparing Two Methods to Follow Patients With Pancreatic Cysts
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04239573
Conditions
Pancreatic Carcinoma
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
Computed Tomography
Endoscopic Ultrasound
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT06319027
Conditions
Glioblastoma, IDH-Wildtype
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Fluciclovine F18
Gadolinium-Chelate
Magnetic Resonance Spectroscopy
Positron Emission Tomography